177 related articles for article (PubMed ID: 36794337)
1. Autoimmune encephalitis: Should we consider third-line immunotherapies earlier?
Kelly MJ; Irani SR
Eur J Neurol; 2023 May; 30(5):1167-1169. PubMed ID: 36794337
[No Abstract] [Full Text] [Related]
2. Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
Srivastava IN; Van Haren KP
Neurology; 2023 Nov; 101(22):985-986. PubMed ID: 37879941
[No Abstract] [Full Text] [Related]
3. [Autoimmune encephalitis-An update].
Heine J; Duchow A; Rust R; Paul F; Prüß H; Finke C
Nervenarzt; 2023 Jun; 94(6):525-537. PubMed ID: 36515716
[TBL] [Abstract][Full Text] [Related]
4. Passively acquired thyroid autoantibodies from intravenous immunoglobulin in autoimmune encephalitis: Two case reports.
Uchida Y; Kato D; Adachi K; Toyoda T; Matsukawa N
J Neurol Sci; 2017 Dec; 383():116-117. PubMed ID: 29246597
[No Abstract] [Full Text] [Related]
5. Challenging diagnosis and treatment decision of a long-history autoantibody-negative autoimmune encephalitis.
Calvat P; Leung C; Bost C; Fortenfant F; Simonetta-Moreau M; Pariente J; Rafiq M; Brefel-Courbon C; Rascol O; Fabbri M; Ory-Magne F
Parkinsonism Relat Disord; 2023 Feb; 107():105232. PubMed ID: 36509623
[No Abstract] [Full Text] [Related]
6. Autoimmune encephalitis: recent clinical and biological advances.
Varley JA; Strippel C; Handel A; Irani SR
J Neurol; 2023 Aug; 270(8):4118-4131. PubMed ID: 37115360
[TBL] [Abstract][Full Text] [Related]
7. NMDAR-directed CAAR T cells show promise for autoimmune encephalitis.
Flemming A
Nat Rev Immunol; 2023 Dec; 23(12):786. PubMed ID: 37938795
[No Abstract] [Full Text] [Related]
8. An Overview of Autoimmune and Paraneoplastic Encephalitides.
Bradshaw MJ; Linnoila JJ
Semin Neurol; 2018 Jun; 38(3):330-343. PubMed ID: 30011413
[TBL] [Abstract][Full Text] [Related]
9. [Autoimmune encephalitis-Challenges and management in intensive medical care].
Brämer D; Geis C; Günther A
Nervenarzt; 2023 Feb; 94(2):113-119. PubMed ID: 36651935
[TBL] [Abstract][Full Text] [Related]
10. Challenging diagnosis and treatment decision of a long-history autoantibody-negative autoimmune encephalitis: Expert commentary.
Abboud H
Parkinsonism Relat Disord; 2023 Feb; 107():105278. PubMed ID: 36609094
[No Abstract] [Full Text] [Related]
11. Immunoadsorption for autoimmune encephalitis.
Fassbender C; Klingel R; Köhler W
Atheroscler Suppl; 2017 Nov; 30():257-263. PubMed ID: 29096847
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of autoimmune encephalitis in Brazil: an urgent call to action.
Dutra LA
Arq Neuropsiquiatr; 2024 Feb; 82(2):1-2. PubMed ID: 38395423
[No Abstract] [Full Text] [Related]
13. Autoimmune encephalitis: clinical presentation, investigation and treatment.
Al-Ansari A; Robertson NP
J Neurol; 2021 Oct; 268(10):3935-3937. PubMed ID: 34546417
[No Abstract] [Full Text] [Related]
14. Antibody-Mediated Autoimmune Encephalitis in Childhood.
Brenton JN; Goodkin HP
Pediatr Neurol; 2016 Jul; 60():13-23. PubMed ID: 27343023
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiological Effects of Autoantibodies in Autoimmune Encephalitides.
Ryding M; Mikkelsen AW; Nissen MS; Nilsson AC; Blaabjerg M
Cells; 2023 Dec; 13(1):. PubMed ID: 38201219
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders.
López-Chiriboga AS; Flanagan EP
Semin Neurol; 2018 Jun; 38(3):392-402. PubMed ID: 30011418
[TBL] [Abstract][Full Text] [Related]
17. DPPX autoimmune encephalitis: A short report on two patients presenting with classic features of this rare but treatable disease.
Mbonde AA; Gritsch D; Arca K; Blech B; McKeon A; Carter J
Mult Scler Relat Disord; 2021 Jul; 52():102934. PubMed ID: 33901970
[No Abstract] [Full Text] [Related]
18. Immunomodulation in the acute phase of autoimmune encephalitis.
Ciano-Petersen NL; Muñiz-Castrillo S; Vogrig A; Joubert B; Honnorat J
Rev Neurol (Paris); 2022; 178(1-2):34-47. PubMed ID: 35000790
[TBL] [Abstract][Full Text] [Related]
19. Pediatric GAD-65 Autoimmune Encephalitis: Assessing Clinical Characteristics and Response to Therapy With a Novel Assessment Scale.
Harmon A; Stingl C; Rikhi A; Tran L; Pizoli C; Malinzak M; Van Mater H
Pediatr Neurol; 2022 Mar; 128():25-32. PubMed ID: 35032887
[TBL] [Abstract][Full Text] [Related]
20. Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.
Wickel J; Chung HY; Platzer S; Lehmann T; Prüss H; Leypoldt F; Günther A; Scherag A; Geis C;
Trials; 2020 Jul; 21(1):625. PubMed ID: 32641101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
